Natural nutrient for improved management of blood glucose in diabetes patients

Type 2 Diabetes and insulin resistance are major health risks, the incidence of which is increasing in all parts of the world

BioKier is developing oral products designed to mimic the effects of malabsorptive gastric bypass surgery which is the most effective treatment for diabetes. In this way, BioKier intends to change the way diabetes is managed and improve the lives of millions of patients worldwide.

BioKier Awarded The $1.6 million Fast-Track Small Business Innovation Research Grant

BioKier has been awarded a $1.6 million Fast-Track Small Business Innovation Research (SBIR) Grant by The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).. Read More

What Is BioKier?

BioKier is an early-stage medical food and pharmaceutical company developing new proprietary products for diabetes and related disorders. BioKier has identified a therapeutic opportunity and is developing a novel oral product for management and treatment for type 2 diabetes and related comorbidities. This product will potentially also have effects in metabolic syndrome and obesity.

BioKier's Partners

BioKier, Inc. has created a network of partnerships with experts in pharmaceutical development, medical treatment, business strategy, law, and laboratory services. This allows BioKier to utilize specialized guidance and advice at every step of the development process.

Recent News

Q&A: BioKier

Recently David Menzies from Carolina Tech News interviewed Dr George Szewczyk, CEO of BioKier, Inc.   Read More

Australian Patent Office has accepted BioKier patent application.
Australian Patent Office has accepted BioKier patent application number 2012250877 and a notice of the acceptance will Read More

First European patent granted for BioKier
BioKier has been informed by European Patent Office that the examining division intends to grant a European patent on Read More

Contact Us!